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sient increase of liver enzymes with male gender as risk fac-
tor (p = 0.008, OR 8.62, 95% CI 1.74–41.66).  Conclusions: Iron 
deficiency and anemia are frequent in IBD patients. Treat-
ment with ferric carboxymaltose is efficious, safe and well 
tolerated in iron-deficient IBD patients. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Iron deficiency is common in patients with inflamma-
tory bowel disease (IBD), affecting up to 80% of all pa-
tients and leading to anemia in approximately one third 
of all IBD patients  [1, 2] . In IBD, iron deficiency is caused 
by dietary restrictions, iron malabsorption due to active 
disease or intestinal blood loss. Moreover, the chronic in-
testinal inflammation in IBD patients leads to an upregu-
lation of proinflammatory cytokines (e.g. IL-1  , IL-6) 
and consecutively hepcidin, which results in an impaired 
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 Abstract 
 Background and Aims: We analyzed iron deficiency and the 
therapeutic response following intravenous ferric carboxy-
maltose in a large single-center inflammatory bowel disease 
(IBD) cohort.  Methods: 250 IBD patients were retrospective-
ly analyzed for iron deficiency and iron deficiency anemia. A 
subgroup was analyzed regarding efficacy and side effects 
of iron supplementation with ferric carboxymaltose.  Re-
sults: In the cohort (n = 250), 54.4% of the patients had serum 
iron levels  ^  60   g/dl, 81.2% had ferritin  ^  100 ng/ml, and 
25.6% had hemoglobin (Hb) of  ^  12 g/dl (females) or  ^  13
g/dl (males). In the treatment subcohort (n = 80), 83.1% of
the patients had iron  ^  60   g/dl, 90.4% had ferritin  ^  100 
ng/ml, and 66.7% had Hb  ^  12/13 g/dl before ferric carboxy-
maltose treatment. After a median dose of 500 mg ferric car-
boxymaltose, 74.7% of the patients reached iron  1 60   g/dl, 
61.6% had ferritin  1 100 ng/ml, and 90.7% reached Hb  1 12/13 
g/dl at follow-up (p  ! 0.0001 for all parameters vs. pretreat-
ment values). The most frequent adverse event was a tran-
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intestinal iron uptake from the gut and sequestering of 
iron in the reticuloendothelial system. Hepcidin inhibits 
iron uptake by interaction with the iron export protein 
ferroportin, which is located on the cell surface of hepa-
tocytes, macrophages and the basolateral membrane of 
enterocytes  [3–5] . This mechanism represents a major 
cause of iron deficiency and associated anemia of chron-
ic disease in IBD and other chronic inflammatory dis-
eases  [6] .
 For the treatment of iron deficiency anemia, the pre-
ferred route of iron supplementation in IBD is intrave-
nous, although many patients would also respond to oral 
iron. However, intravenous iron is more effective, better 
tolerated, and improves the quality of life to a greater ex-
tent than oral iron supplements. Absolute indications for 
intravenous iron include severe anemia (Hb  ! 10 g/dl), 
intolerance, or inappropriate response to oral iron, severe 
intestinal disease activity, concomitant therapy with 
erythropoietin, or patient preference. Oral iron supple-
ments can be used if absolute indications for intravenous 
iron therapy are not met and the response and tolerance 
should be monitored, and treatment should be changed 
to intravenous iron preparations if necessary. Several 
clinical trials clearly demonstrated that intravenous iron 
supplementation has better efficacy, tolerability and long-
term response than oral iron treatment  [7–9] . Further-
more, in animal models, there is evidence that oral iron 
supplements lead to oxidative stress in the gut and may 
aggravate disease activity  [10, 11] . These observations 
have also been made in IBD patients  [12, 13] .
 Ferric carboxymaltose (Ferinject  ; Vifor Pharma, 
Glattbrugg, Switzerland) is a novel, optimized iron for-
mulation for intravenous application. It is a water-soluble, 
macromolecular iron hydroxy-complex consisting of 
polynuclear iron (III) hydroxide with a molecular weight 
of 150 kDa. Efficacy of ferric carboxymaltose has been 
demonstrated in various studies, including treatment of 
anemia in chronic kidney disease, chronic heart failure, 
post-partum anemia and IBD  [14–19] . In the latter trial, 
ferric carboxymaltose was non-inferior to oral adminis-
tered ferrous sulfate in terms of hemoglobin (Hb) change 
over 12 weeks. However, there was superiority in provid-
ing a faster Hb response, a higher increase in iron stores, 
and a better patient tolerance  [14] . There are additional 
advantages of ferric carboxymaltose in clinical practice. 
For instance, high doses of iron can be administered in a 
short infusion time (max. 1,000 mg as infusion in 15 min; 
up to 200 mg as i.v. bolus). Even the risk of side effects re-
garding toxicity and hypersensitivity seems to be lower 
compared with other intravenous iron formulations  [20] . 
Therefore, ferric carboxymaltose has been used in our 
outpatient clinic for the treatment of iron deficiency and 
iron deficiency anemia since its approval in Germany in 
November 2007.
 Given that all large trials using ferric carboxymaltose 
were pharmaceutical company sponsored resulting in 
potential conflicts of interest, we aimed in this study 
without pharmaceutical sponsoring to analyze the iron 
status in IBD patients and to investigate the efficacy and 
safety of ferric carboxymaltose for iron supplementation 
in IBD patients in clinical practice in a large single-center 
cohort. 
 Materials and Methods 
 Study Cohort 
 Medical and laboratory records of all patients, who visited our 
IBD center for the first time in 2008 (n = 250), were analyzed for 
iron parameters, including serum iron, serum ferritin and Hb 
values. Iron values of  ^  60   g/dl and ferritin  ^  100 ng/ml were 
considered as clinically relevant and defined as pathologic in this 
study. According to the WHO definition, anemia is defined as a 
decline in blood hemoglobin to a concentration of !12 g/dl (120 
g/l) in women and of !13 g/dl (130 g/l) in men. Therefore, these 
values were considered pathologic in this study.
 Out of this cohort, we identified 80 patients who were treated 
with ferric carboxymaltose at least for one dose of 100 mg. Indica-
tions for ferric carboxymaltose treatment were serum iron levels 
of  ^  60   g/dl and Hb  ^  12/13 g/dl, or iron  ^  60   g/dl, ferritin 
 ^  100 ng/ml and Hb  ^  12/13 g/dl. Patients were also included into 
the study when serum iron was  ^  60   g/dl and ferritin  1 100
ng/ml if there was presence of inflammation (elevated CRP and/
or elevated leukocyte count without previous or ongoing steroid 
treatment).
 Based on the protocol of the FERGIcor trial  [21] , the initial fer-
ric carboxymaltose dose was at least 500 mg. Only in 1 patient 
with allergies against other intravenous iron supplements was an 
initial dose of 100 mg ferric carboxymaltose chosen. The total fer-
ric carboxymaltose dose (range 100–7,500 mg) was dependent on 
the severity of the initial iron deficiency and iron deficiency ane-
mia. Efficacy regarding increase of Hb, iron and ferritin and side 
effects of ferric carboxymaltose treatment, including laboratory 
values (blood count, liver enzymes and LDH), were monitored. 
Patients were followed up for a median time interval of 20 weeks. 
After this study interval, patients with relapsing iron deficiency 
or iron deficiency anemia (as defined in this study) received fur-
ther treatment with ferric carboxymaltose.
 Statistical Analysis 
 Data were summarized by adequate measures of location and 
spread for continuous variables and by proportions for discrete 
variables. Adequate two-sample tests for continuous data (t test, 
Mann-Whitney U test) and for discrete data (  2 tests, Fisher’s exact 
test) were used. For the prediction of liver enzyme elevation, we 
used a logistic regression model where predictors were selected 
from a potential set of predicting variables [serum iron, ferritin, 
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serum CRP, age, duration of IBD, gender, type of IBD (Crohn’s 
disease or ulcerative colitis), body mass index (BMI), concomitant 
treatment with immunosuppressive agents or anti-TNF antibod-
ies] by relying on the multivariate fraction polynomials (mfp) al-
gorithm which simultaneously allows for testing non-linear rela-
tionships of continuous predictors and the outcome. To identify 
patient groups with the greatest risk for anemia, we used a logistic 
regression model similar to the previous one including all patients 
with iron deficiency anemia (excluding patients with macrocytic 
anemia) and anemia Hb levels  ^  12/13 g/dl as outcome predictor. 
The corresponding set of potential predictors was serum iron, fer-
ritin, serum CRP, age, gender, type of IBD, disease duration, BMI, 
concomitant treatment with immunosuppressives or anti-TNF 
antibodies and MCV. For predicting ferritin, we built a linear re-
gression model by relying on the mfp algorithm where the poten-
tial predictors gender, iron, CRP, Hb and BMI were considered. To 
satisfy the normality assumption, we took the natural logarithm 
of ferritin for modeling purposes. Using the same method, we de-
veloped a model for predicting Hb from the potential predictors 
ferritin, CRP, iron and gender. Based on the final linear regression 
model for Hb, we were able to construct prediction intervals for an 
individual case’s Hb value given the values of the selected predic-
tors. Further, the assumptions of the regression models were eval-
uated by using graphically based residual analyses. All statistical 
tests were performed two-sided, a p value of  ! 0.05 was considered 
as statistically significant. All statistical analyses were performed 
by using R (version 2.12.1) and PASW Statistics 17.0.
 Results 
 Prevalence of Iron Deficiency and Iron Deficiency 
Anemia in IBD Patients 
 Iron parameters and Hb levels of 250 IBD patients, 
who visited our IBD center for the first time from January 
2008 to December 2008, were analyzed. Crohn’s disease 
was diagnosed in 67.6% (n = 169), ulcerative colitis in 
32.4% (n = 81); 55.6% (n = 139) were females, 44.4% (n = 
111) were males. There was a high prevalence of iron de-
ficiency among these patients. Serum iron levels of  ^  60 
  g/dl were seen in 136 patients (54.4%), 203 patients 
(81.2%) had ferritin levels  ^  100 ng/ml and 64 patients 
(25.6%) were anemic with Hb levels  ^  12/13 g/dl ( table 1 ). 
Iron deficiency anemia with iron values  ^  60   g/dl, fer-
ritin levels  ^  100 ng/ml and Hb levels  ^  12/13 g/dl were 
found in 44 patients (17.6%). In this study, we defined Hb 
levels  ^  12/13 g/dl as anemia of chronic disease, when 
 concomitantly serum ferritin levels were  6 100 ng/ml 
and CRP serum levels were  1 0.5 mg/dl. Only 9 patients 
(3.6%) met these criteria.
 Predictors of Microcytic Anemia in IBD Patients 
 Multivariate logistic regression analyses demonstrat-
ed a stronger effect of serum iron than ferritin levels on 
the prediction of microcytic anemia. This analysis re-
vealed (logarithmized) serum iron (p  ! 2.38  ! 10 –10 ) 
with an odds ratio (OR) of 0.03 [95% confidence interval 
(CI) 0.01–0.09] and (logarithmized) ferritin (p = 1.25  ! 
10 –4 ) with an OR of 0.29 (95% CI 0.15–0.55) as risk factors 
for the development of microcytic anemia.
 Ferritin levels are modulated by the degree of inflam-
mation (as reflected by CRP values). Similarly, in our 
study cohort, ferritin levels were significantly influenced 
by the (logarithmized) serum CRP levels (p = 0.005). A 
final linear regression model applied to our IBD study 
population (n = 250) statistically confirmed the effect of 
iron (p  ! 0.001) on Hb. As expected, gender also showed 
statistically significant differences in predicting Hb levels 
(p  ! 0.001) with higher Hb values in males. Additionally 
the mfp algorithm revealed a non-linear relationship be-
tween iron and Hb as shown in  figure 1 . For predicting 
the mean Hb value based on serum iron level (labeled in 
the formula as ‘iron’) and gender, the linear predictor of 
the final regression model can be used which is given by: 
2
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 The corresponding 50 and 95% Hb prediction inter-
vals based on serum iron levels are shown in  figure 2 a and 
b separately for male and female IBD patients. The per-
centiles in these figures may be helpful for deciding when 
intravenous iron supplementation should be started; 
however, considering the high variability of serum iron 
levels, these figures cannot replace more reliable param-
Table 1.  Demographic and clinical characteristics of the whole 
study cohort (n = 250)
Demographic and clinical characteristics Patients
Male/female 111/139 (44.4/55.6)
Median age, years 36.9 (18–74)
CD/UC 169/81 (67.6/32.4)
Median duration of disease, years 8 (2–38)
Iron ≤60 g/dl 136 (54.4)
Ferritin ≤100 ng/ml 203 (81.2)
Hb levels ≤12/13 g/dl 64 (25.6)
CRP >0.5 mg/dl 142 (56.8)
Anti-TNF- antibody-treated patients 146 (58.4)
Patients treated with
Immunosuppressives 179 (71.6)
Systemic corticosteroids 56 (22.4)
Values are numbers with percentages or range in parentheses.
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eters of measuring the iron status such as transferrin sat-
uration or soluble transferrin receptor.
 Efficacy of Ferric Carboxymaltose Treatment 
 Out of the whole patient cohort (n = 250), 80 patients 
were treated with ferric carboxymaltose and were fol-
lowed up for a median of 20 weeks (range 1–60). In this 
subgroup, 61.3% had Crohn’s disease (n = 49), 38.7% ul-
cerative colitis (n = 31), 56.2% (n = 45) were females and 
43.8% (n = 35) were males. Total cumulative ferric car-
boxymaltose doses during the follow-up period ranged 
from 100 to 7,500 mg (see details in the Materials and 
Methods section). The median dose was 500 mg ( table 2 ).
 Seventy-one patients had complete data on iron pa-
rameters and Hb levels to be analyzed for efficacy of fer-
ric carboxymaltose treatment. Before treatment with fer-
ric carboxymaltose, 83.1% of the patients (n = 59) had 
serum iron levels of  ^  60   g/dl, while only 16.9% of the 
patients had normal serum iron levels. In the follow-up 
period and after a median dose of 500 mg ferric carboxy-
maltose, 74.6% (n = 53) reached the target serum iron 
level of  1 60   g/dl ( fig. 3 a; p  ! 0.001) versus pretreatment 
levels.
 Ferritin levels were analyzed in 73 patients treated 
with ferric carboxymaltose. Before treatment with ferric 
carboxymaltose, 90.4% of the patients (n = 66) had serum 
ferritin  ^  100 ng/ml, while only 9.6% had ferritin values 






















 Fig. 1. Scatter plot of Hb values versus serum iron levels stratified 
by gender. The predicted mean values based on the final linear 














































 Fig. 2. Mean values and 50 and 95% prediction intervals for Hb 
based on serum iron levels for males ( a ) and females ( b ). 
Table 2.  Demographic and clinical characteristics of the subco-
hort with ferric carboxymaltose treatment (n = 80)
Demographic and clinical characteristics Patients
Male/female, n (%) 35/45 (43.8/56.2)
Median age, years (range) 35.2 (18–70)
CD/UC, n (%) 49/31 (61.3/38.7)
Median duration of disease, years (range) 7 (2–30)
Median dose of ferric carboxymaltose, mg 
(range) 500 (100–7,500)
Median follow-up, weeks (SD) 20 (12)
Iron ≤60 g/dl, n (%) 59 (83.1)
Ferritin ≤100 ng/ml, n (%) 66 (90.4)
Hb levels ≤12/13 g/dl, n (%) 50 (66.7)
CRP >0.5 mg/dl, n (%) 39 (48.8)
Anti-TNF- antibody-treated patients, n (%) 59 (73.7)
Patients treated with
Immunosuppressives, n (%) 46 (57.5)
Systemic corticosteroids, n (%) 4 (5.0)
CD/UC = Crohn’s disease/ulcerative colitis.
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dose of 500 mg ferric carboxymaltose, 61.6% (n = 45) 
reached the ferritin target value of  1 100 ng/ml ( fig. 3 b; 
p  ! 0.001) versus pretreatment levels.
 Seventy-five patients were analyzed regarding changes 
of Hb levels under ferric carboxymaltose treatment. Be-
fore treatment, 66.7% of the patients (n = 50) had Hb lev-
els  ^  12/13 g/dl, while only one third (33.3%; n = 25) had 
normal Hb levels. After a median dose of 500 mg ferric 
carboxymaltose, 90.7% (n = 68) reached Hb levels  1 12/13 
g/dl in the follow-up period ( fig. 3 c; p  ! 0.001) versus pre-
treatment levels.
 Side Effects of Ferric Carboxymaltose 
 During the median follow-up period of 20 weeks, 
17.5% of the patients (n = 14) developed side effects asso-
ciated with ferric carboxymaltose treatment. The most 
frequent adverse event was a transient increase of liver 
enzymes (APT and/or ALT) of greater than two times the 
upper normal limit, which occurred in 12 patients (15.0%) 
and completely resolved at follow-up. One patient com-
plaint about headaches after the infusion (1.25%) and 1 
patient developed feet edema (1.25%;  table 3 ). 
 Predictors of Abnormal Liver Function Tests in Ferric 
Carboxymaltose-Treated IBD Patients 
 Given that a transient increase of liver enzymes was 
the most frequent side effect of ferric carboxymaltose 
treatment within the follow-up period, we aimed to iden-
tify predictors for the development of increased liver en-
zymes using multivariate analysis and pretreatment pa-
rameters (  -GT, Hb, serum iron levels, ferritin, CRP) and 
age, gender, type of IBD (Crohn’s disease or ulcerative 
colitis), BMI, concomitant treatment with immunosup-
pressives or anti-TNF antibodies and cumulative dose 
ferric carboxymaltose as predictor variables. Multivari-
ate analyses revealed only male gender (p = 0.008, OR 
8.621, 95% CI 1.74–41.66) as risk factor for the develop-
ment of increased liver enzymes.
 Discussion 
 In our single-center cohort, we found a high preva-
lence of iron deficiency and anemia, which is consistent 
with findings of other studies in IBD patients  [1, 2, 22] . 
Given that anemia is the most common systemic compli-
Table 3. S ide effects in the ferric carboxymaltose treatment group 
(n = 80)
Side effect Patients, n (%)
Increase of liver enzymes 12 (15)
Headache 1 (1.25)
































































 Fig. 3. Percentages of patients with iron values  1 60 and  ^  60   g/dl ( a ), ferritin values  1 100 and  ^  100 mg/dl ( b ), and Hb values  1 12/13 
and  ^  12/13 g/dl ( c ) before ferric carboxymaltose treatment (preFCM) and at follow-up after a median dose of 500 mg ferric carboxy-
maltose. 
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cation in IBD patients, treatment of iron deficiency, which 
is the major cause for anemia in these patients, is an im-
portant goal in IBD treatment  [23–25] . In our patient co-
hort, iron, ferritin and Hb restorage was achieved with a 
median dose of 500 mg ferric carboxymaltose in the ma-
jority of the patients with very low side effects. The most 
frequent side effect was a transient increase of liver en-
zymes, particularly in male patients.
 The present study was limited by the lack of sufficient 
data for most patients regarding transferrin saturation 
and soluble transferrin receptor, which are important 
laboratory parameters of iron status in patients with 
systemic inflammation, in which serum ferritin levels 
may be increased despite iron deficiency  [26] . Similarly, 
in our IBD cohort, ferritin levels were significantly 
modulated by the serum CRP levels. Using a linear re-
gression model, we demonstrate a non-linear relation-
ship between iron and Hb. In addition, we provide Hb 
percentile curves based on the serum iron levels which 
may be a helpful tool for deciding when intravenous iron 
supplementation should be started in IBD patients. 
However, we have to acknowledge that serum iron levels 
are influenced by a number of factors and are much less 
reliable than transferrin saturation or soluble transfer-
rin receptor.
 In the past, oral iron supplementation has been com-
monly used in IBD patients. While oral iron supplemen-
tation is suitable and effective in patients without malab-
sorption, side effects like nausea and constipation and 
insufficient restorage of iron and Hb levels limit the use 
of oral iron formulations. In addition, several studies 
demonstrated that oral iron induces oxidative stress in 
the gut and aggravates inflammation  [11, 27] . In IBD pa-
tients, there is often the need for high iron doses due to 
very low iron stores, resulting from chronic bleeding or 
inflammatory conditions  [2, 28, 29] .
 For administration of high iron doses, most approved 
intravenous formulations like low or high molecular 
weight iron dextran, iron sucrose and sodium ferric glu-
conate have to be given several times with long infusion 
times to reach target iron/Hb values. In addition, several 
of these agents, particularly high molecular weight iron 
dextran, may have side effects like severe anaphylactic 
reactions.
 Ferric carboxymaltose, a novel iron formulation, was 
approved for treatment of iron deficiency and iron defi-
ciency anemia in Europe in 2007. Several studies in pa-
tients with different disease entities demonstrated im-
proved symptoms, functional capacity and quality of life, 
while the side-effect profile was acceptable  [14, 15, 30, 31] . 
 In this study, the initial ferric carboxymaltose dose 
was based on data of the randomized controlled FERGI-
cor trial  [21] , in which all patients received initially at 
least 500 mg ferric carboxymaltose. This simpler ferric 
carboxymaltose-based dosing regimen showed better ef-
ficacy and compliance compared with the Ganzoni-cal-
culated iron sucrose dose regimen  [21] . Our results sup-
port the data of the FERGIcor trial  [21] and demonstrate 
that in the majority of patients encountered in daily prac-
tice, a single 500 mg ferric carboxymaltose infusion is 
sufficient to treat iron deficiency and mild iron deficien-
cy anemia.
 Although comparative studies analyzing efficacy are 
rare, there are data regarding side effects. In a clinical 
trial including patients with chronic kidney disease un-
dergoing hemodialysis, a lower proportion of ferric car-
boxymaltose than iron sucrose recipients experienced at 
least one drug-related adverse event (5 vs. 10.2%: p value 
not reported). However, there were no statistically sig-
nificant differences between the groups regarding other 
parameters of drug tolerability  [32] . The tolerability and 
safety profile of ferric carboxymaltose has been summa-
rized in an abstract which included ten studies with 
 1 2,000 patients treated with ferric carboxymaltose  [33] . 
According to this summary, 15.3% of ferric carboxymalt-
ose recipients and 26.1% of oral ferrous sulfate recipients 
reported at least one drug-related adverse event. Head-
ache, the most frequently reported adverse event related 
to ferric carboxymaltose, occurred in  ! 3% of patients of 
both treatment groups which is consistent with our study, 
in which only 1 patient (1.2%) complained about head-
aches after therapy. Rash and local injection site reactions 
were more common in patients treated with ferric car-
boxymaltose, whereas gastrointestinal adverse events 
(particularly constipation and nausea) were more fre-
quently reported in ferrous sulfate recipients across the 
trials  [20] . The very recently released data of the FERGI-
cor trial  [21] demonstrate that hyperferritinemia and 
transient hypophosphatemia may be an additional side 
effect of ferric carboxymaltose treatment.
 Toxicity of iron treatment is well known. The concen-
tration of non-transferrin-bound iron/free iron has 
been shown to correlate with an increase in the inci-
dence of adverse events following intravenous adminis-
tration of iron sucrose  [34] . It has been proposed that 
non-transferrin-bound iron may catalyze a number of 
reactions that in turn lead to oxidative stress and mem-
brane damage.
 As a mechanism of iron deficiency, hepcidin repre-
sents a key regulator of iron metabolism. When using po-
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tent anti-inflammatory drugs like anti-TNF antibodies, 
hepcidin may be downregulated. This in turn leads to an 
increased iron mobilization and uptake from the gut  [35] , 
which may result in a functional increase in iron defi-
ciency. To treat the higher demand for iron in this situa-
tion, transitional high-dose iron supplementation is nec-
essary  [36] . Hence, by the early use of highly effective
anti-inflammatory therapeutics (i.e. anti-TNF antibod-
ies) in IBD patients with the goal of mucosal healing, 
long-term incidence of iron deficiency may decrease in 
the future  [37] .
 In summary, iron deficiency and anemia are very com-
mon in IBD patients. As we demonstrated in our study, 
ferric carboxymaltose is a very efficient and well-tolerated 
therapy in IBD patients. In this cohort, transient liver en-
zyme elevations were the most common side effect. A sin-
gle dose of 500 mg ferric carboxymaltose was sufficient to 
normalize Hb levels in the majority of iron-deficient IBD 
patients. Limitations of this study include its retrospective 
nature and the lack of transferrin saturation levels in the 
majority of patients. Further prospective studies with 
larger patient cohorts are needed to clarify the advantages 
and cost-effectiveness of ferric carboxymaltose compared 
to other intravenous iron formulations.
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